NCT02638233View on ClinicalTrials.gov

Therapy With Ledipasvir/Sofosbuvir in Patients With Genotype 1 HCV Infection Receiving Opiate Substitution Therapy

PHASE4UnknownINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions

Chronic Hepatitis C

Interventions

DRUG

Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)

Trial Locations (1)

1160

RECRUITING

Wilhelminenspital, Vienna

Sponsors

Collaborators (1)

Gilead Sciences

All Listed Sponsors

collaborator

Gilead Sciences

INDUSTRY

lead

Wilhelminenspital Vienna

OTHER

NCT02638233 - Therapy With Ledipasvir/Sofosbuvir in Patients With Genotype 1 HCV Infection Receiving Opiate Substitution Therapy | Biotech Hunter | Biotech Hunter